Trends and comparisons of diabetes burden in China and the world from 1990 to 2021,with forecasts to 2050:a systematic analysis of the global burden of disease study 2021

1990年至2021年中国与世界糖尿病负担趋势及比较,并预测至2050年:2021年全球疾病负担研究的系统分析

阅读:2

Abstract

BACKGROUND: Diabetes is a major global public health issue. This study investigated the trends in the age-and gender-specific burden of diabetes in China and worldwide from 1990 to 2021, and predicted the prevalence of diabetes in 2050. METHODS: Using publicly available data from the Global Burden of Disease (GBD) database from 1990 to 2021, we comprehensively applied Joinpoint regression and age-period-cohort (APC) analysis to reveal the epidemiological characteristics, conducted decomposition analysis to identify the driving factors of burden changes, and used the autoregressive integrated moving average (ARIMA) model to project the disease burden of diabetes from 2022 to 2050. RESULTS: From 1990 to 2021, both in China and globally, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized disability-adjusted life year rate (ASDR) of diabetes showed an upward trend. In contrast, China's age-standardized mortality rate (ASMR) of diabetes decreased, while the global ASMR increased. The average annual percentage changes (AAPC) of China's ASIR, ASPR, ASMR, and ASDR were 1.29, 1.76,- 0.30, and 0.76% respectively, compared with 1.74, 2.10, 0.25, and 1.05% for the global diabetes burden. CONCLUSIONS: In China, the incidence, prevalence, and Disability-Adjusted Life Years (DALYs) of diabetes increased, while the mortality rate decreased. It is projected that by 2050, the number of diabetes patients in China will reach 84.01 million, and globally, it will reach 1038.2 million. Given China's large population and the trend of population aging, it is essential to formulate targeted prevention and control strategies to address the challenge of diabetes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。